B cells as a target of immune modulation

Area of Science:

• Immunology
• Neuroscience
• Pathology

Background:

• B cells are integral to the immune system, involved in autoimmunity via antigen presentation, antibody secretion, and complement activation.
• Animal models and human studies suggest B cell activation contributes to myelin destruction and worse prognosis in multiple sclerosis (MS).
• While T cells have been primary therapeutic targets, recent focus has shifted to B cells' role in MS pathogenesis.

Purpose of the Study:

• To explore the role of B cells in the pathogenesis of multiple sclerosis (MS).
• To review the rationale for developing B cell-targeted therapeutics for MS.
• To highlight the shift in therapeutic strategies from T cells to B cells in MS treatment.

Main Methods:

• Review of existing literature on B cell involvement in MS.
• Analysis of animal models of MS.
• Examination of clinical trial data for B cell-targeted therapies like rituximab.

Main Results:

• B cells contribute to myelin destruction in MS through activation and plasmablast formation.
• MS patients with B cell involvement show a poorer prognosis.
• Rituximab treatment significantly decreases new lesions and relapses in MS patients, indicating B cell efficacy.

Conclusions:

• B cells play a significant role in the immune pathogenesis of MS.
• Targeting B cells, particularly CD20-expressing cells, is a viable therapeutic strategy for MS.
• Immune modulation of B cells holds promise for ameliorating MS and improving patient outcomes.